Search results

693 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter
Cancer service guidelines Remove Cancer service guidelines filter

Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

In development [GID-TA10024] Expected publication date: 28 June 2017

Type

Technology appraisal guidance

Status

In development
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

In development [GID-TA10046] Expected publication date: 22 November 2017

Type

Technology appraisal guidance

Status

In development
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Inpatient mental health settings

In development [GID-SGWAVE0701] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]

In development [GID-TAG431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

In development [GID-TAG363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

In development [GID-TAG425] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pulmonary arterial hypertension (adults) - drugs [ID12]

In development [GID-TAG382] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]

In development [GID-TAG444] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Community nursing care settings

In development [GID-SGWAVE0700] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Breast cancer - intensity modulated radiotherapy [ID16]

In development [GID-TAG390] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

In development [GID-TAG393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Management and organisational approaches to safe staffing

In development [GID-SGWAVE0761] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

In development [GID-TAG433] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Thrombophilia [ID393]

In development [GID-TAG374] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Systemic lupus erythematosus - prasterone [ID392]

In development [GID-TAG373] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Implanting a baroreceptor stimulation device for resistant hypertension

In development [GID-IP1180] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]

In development [GID-TAG436] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell) - cetuximab [ID9]

In development [GID-TAG395] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (prevention) - rivaroxaban [ID463]

In development [GID-TAG427] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Heart failure (acute) - serelaxin [ID673]

In development [GID-TAG454] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

In development [GID-TAG332] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Macular oedema (diabetic) - pegaptanib sodium [ID452]

In development [GID-TAG280] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]

In development [GID-TAG528] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Accident and emergency departments

In development [GID-SGWAVE0762] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Juvenile idiopathic arthritis - abatacept [ID27]

In development [GID-TAG402] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

In development [GID-TAG424] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma - bortezomib (consolidation therapy) [ID529]

In development [GID-TAG320] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

In development [GID-TAG435] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Generalised anxiety disorder - quetiapine [ID347]

In development [GID-TAG421] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia [ID3831]

Proposed [GID-TA10736] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lung transplantation with ex-vivo perfusion

In development [GID-IP1046] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development